Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.73 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.73 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.73 |
| ▸ | MAP1LC3A | Q9H492 | 2/20 | 0.73 |
| ▸ | POLQ | O75417 | 1/20 | 0.73 |
| ▸ | ALB | P02768 | 1/20 | 0.73 |
| ▸ | KDR | P35968 | 1/20 | 0.73 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21363200 | 1.00 | HSP90AB1 (0.73) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3APOLQ | |
| SCHEMBL10306489 | 1.00 | HSP90AB1 (0.73) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3APOLQ | |
| SCHEMBL17049899 | 1.00 | HSP90AB1 (0.73) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3APOLQ | |
| SCHEMBL13644903 | 1.00 | HSP90AB1 (0.73) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3APOLQ | |
| SCHEMBL24589015 | 0.92 | HSP90AB1 (0.68) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3APOLQ | |
| SCHEMBL22023535 | 0.91 | HSP90AB1 (0.68) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3APOLQ | |
| SCHEMBL21363030 | 0.91 | HSP90AB1 (0.68) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3APOLQ | |
| SCHEMBL22023815 | 0.91 | HSP90AB1 (0.68) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3APOLQ | |
| SCHEMBL21363211 | 0.91 | HSP90AB1 (0.67) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3APOLQ | |
| SCHEMBL21362996 | 0.90 | HSP90AB1 (0.67) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3APOLQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807440-B1 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | UNIV KANSAS (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-8212012-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-7960353-B2 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | UNIVERSITY OF KANSAS (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | US | disclosed |
| US-7811998-B2 | Novobiocin analogues as anticancer agents | UNIVERSITY OF KANSAS (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100105630-A1 | NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS | UNIVERSITY OF KANSAS (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100048882-A1 | Novobiocin Analogues as Anticancer Agents | UNIVERSITY OF KANSAS (US) | 2010-02-25 | — | — | US | disclosed |
| US-7622451-B2 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | UNIVERSITY OF KANSAS (US) | 2009-11-24 | — | — | US | disclosed |
| US-7608594-B2 | Novobiocin analogues as anticancer agents | UNIVERSITY OF KANSAS (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105630-A1 | NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS | SSB, IAPP, NLN | HSP90AB1 181/4885HSP90AA1 529/4885MAP1LC3B 246/4885 |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | HSP90AB1, HSP90B1, HSP90AB2P | HSP90AB1 1/4885HSP90AA1 4/4885MAP1LC3B 217/4885 |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AB1 1/4885HSP90AA1 4/4885MAP1LC3B 1831/4885 |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, HSP90B1 | HSP90AB1 13/4885HSP90AA1 17/4885MAP1LC3B 3413/4885 |
| US-20100048882-A1 | Novobiocin Analogues as Anticancer Agents | HSP90B1, HSP90AB2P, HSP90AB1 | HSP90AB1 3/4885HSP90AA1 7/4885MAP1LC3B 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.